2.Wolfson WC.POHEM—a framework for understanding and modeling the health of human populations. World Health Stat Q. 1994;47:157–176.
4.Canadian Cancer Society's Steering Committee. Canadian cancer statistics 2009. Toronto: Canadian Cancer Society, 2009.
5.Moller H, Fairley L, Coupland V, et al.The future burden of cancer in England: incidence and numbers of new patients in 2020. Br J Cancer. 2007;96:1484–1488.
7.National Lung Screening Trial Research Team. Reduced lung-cancer mortality with low-dose computed tomographic screening. N Engl J Med. 2011;365:395–409.
8.Winton T, Livingston R, Johnson D, et al.Vinorelbine plus cisplatin versus observation in resected non-small cell lung cancer. N Engl J Med. 2005;352:2589–2597.
9.Goffin J, Coakley N, Ellis P, et al. Cancer Care Ontario Evidence-based series #7–10. First-line systemic chemotherapy in the treatment of advanced non-small cell lung cancer: Evidentiary base 2009. www.cancercare.on.ca (accessed December 20, 2011). 11.Jonker D, Spithoff K, Maroun J.Adjuvant systemic chemotherapy for stage II and III colon cancer following complete resection: Guidelines recommendations. Evidence-based series #2–29 www.cancercare.on.ca (accessed Month day, year).
12.Segal NH, Saltz LB.Evolving treatment of advanced colon cancer. Annu Rev Med. 2009;60:207–219.
13.Evans WK, Will BP, Berthelot J-M, Wolfson MC.Estimating the cost of lung cancer diagnosis and treatment in Canada: the POHEM model. Can J Oncol. 1995;5:408–419.
14.Maroun J, Ng E, Berthelot J-M, et al.Lifetime costs of colon and rectal cancer management in Canada. Chronic Dis Can. 2003;24:91–101.
15.Will BP, Berthelot J-M, LePetit C, et al.Estimates of the lifetime costs of breast cancer treatment in Canada. Eur J Cancer. 2000;36:724–735.
16.Will BP, Le Petit C, Berthelot J-M, et al.Diagnostic and therapeutic approaches for non-metastatic breast cancer in Canada, and their associated costs. Br J Cancer. 1999;79:1428–1436.
17.Berthelot J-M, Will BP, Evans WK, et al.Decision framework for chemotherapeutic interventions for metastatic non-small cell lung cancer. J Natl Cancer Inst. 2000;92:1321–1329.
18.Evans WK, Will BP, Berthelot J-M, et al.Breast cancer: Better care for less cost: Is it possible? Int J Technol Assess Health Care. 2000;16:1168–1178.
19.Flanagan W, Le Petit C, Berthelot J-M, et al.Potential impact of population-based colorectal cancer screening in Canada. Chronic Dis Can. 2003;24:81–88.
20.Will BP, Berthelot J-M, Nobrega KM, Flanagan W, Evans WK.Canada's Population Health Model (POHEM): A tool for performing economic evaluations of cancer control interventions. Eur J Cancer. 2001;37:1797–1804.
21.Will BP, Nobrega KM, Berthelot J-M, et al.First do no harm: Extending the debate on the provision of preventive tamoxifen. Br J Cancer. 2001;85:1280–1288.
22.Whittemore AS, McMillan A.Lung cancer mortality among US uranium miners: A reappraisal. J Natl Cancer Inst. 1983;71:489–499.
23.Winawer SJ, Zauber AG, Ho MN, et al.Prevention of colorectal cancer by colonoscopic polypectomy. N Engl J Med. 1993;329:1977–1981.
24.Kronborg O, Fenger C, Olsen J, Jorgensen OD, Sondergaard O.Randomized study of screening for colorectal cancer with fecal occult blood test. Lancet. 1996;348:1467–1471.
25.Church TR, Mandel JS, Bond JH, Ederer F.Colorectal cancer incidence reduction due to polyp removal: Results from the Minnesota trial. Gastroenterology. 2003;124 (Suppl 1):A55.
26.Lieberman DA.Screening for colorectal cancer. N Engl J Med. 2009;361:1179–1187.
27.Horsman J, Furlong W, Feeney D, Torrance G.The Health Utilities Index (HUI): Concepts, measurement properties and applications. Health Qual Life Outcomes. 2003;1:54.
30.Evans WK, Connor Gorber SK, Spence ST, Will BP; for the Population Health Impact of Disease in Canada (PHI). Health state descriptions for Canadians. Cancers. Statistics Canada, catalogue no. 82–619-MIE2005001. Ottawa: Statistics Canada, 2005
31.McIntosh CN, Gorber S, Bernier J, Berthelot J-M. Eliciting Canadian population preferences for health states using the Classification and Measurement System of Functional Health (CLAMES). Chron Dis Can. 2007;28:29–41.
32.Flanagan WM, McIntosh CN, Berthelot J-M, LePetit C.Deriving utility scores for co-morbid conditions: a test of the multiplicative model for combining individual condition scores. Popul Health Metr. 2006;4:13 doi:10.1186/1478–7954-4-13.
35.Navaratnam S, Kliever EV, Butler J, et al.Population-based patterns and cost management of metastatic non-small cell lung cancer after completion of chemotherapy until death. Lung Cancer. 2010;70:110–115. doi:10.1016/j.lungcan.2010.01.012.
37.Bordt M, Cameron G, Gribble S, et al.The social policy simulation database and model: An integrated tool for tax/transfer policy analysis. Can Tax J. 1990;38.
39.Butts CA, Ding K, Seymour L, et al.Randomized phase III trial of vinorelbine plus cisplatin compared with observation in completely resected stage IB and II non-small-cell lung cancer: Updated survival analysis of JBR-10. J Clin Oncol. 2009;28:29–34.
40.Evans WK, Feld R, Murray N, et al.Superiority of alternating non-cross-resistant chemotherapy in extensive small cell lung cancer. Ann Int Med. 1987;107:451–458.
41.Feld R, Evans WK, Coy P, et al.Canadian multicentre randomized trial comparing sequential and alternating administration of two non-cross-resistant chemotherapy combinations in patients with limited small-cell carcinoma of the lung. J Clin Oncol. 1987;5:1401–1409.
42.Holmes EC, Gail M, for the Lung Cancer Study Group. Surgical adjuvant therapy for stage II and stage III adenocarcinoma and large-cell undifferentiated carcinoma. J Clin Oncol. 1986;4:710–715.
43.Johnson DH, Einhorn LH, Bartolucci A, et al.Thoracic radiotherapy does not prolong survival in patients with locally advanced, unresectable non-small cell lung cancer. Ann Int Med. 1990;113:33–38.
44.Mountain CM, Gail MH.The Lung Cancer Study Group: Surgical adjuvant intrapleural BCG treatment for stage I non-small cell lung cancer. J Thorac Cardiovasc Surg. 1981;82:649–657.
45.Perez CA, Stanley K, Rubin P, et al.A prospective randomized study of various irradiation doses and fractionation schedules in the treatment of inoperable non-oat-cell carcinoma of the lung: Preliminary Report by the Radiation Therapy Oncology Group. Cancer. 1980;45:2744–2753.
46.Rapp E, Pater JL, Willan A, et al.Chemotherapy can prolong survival in patients with advanced non-small cell lung cancer. Report of a Canadian multicentre randomized trial. J Clin Oncol. 1988;6:633–641.
47.McGregor R, Vasudev P, Letourneau E, et al.Background concentration of radon and radon daughters in Canadian homes. Health Phys. 1980;39:285–289.
48.Eheman C, Henley SJ, Ballard-Barbash R, et al.Annual report to the nation on the status of cancer 1975–2008, featuring cancers associated with excess weight and lack of sufficient physical activity. Cancer. 2012;118:2338–2366. doi:10.1002/cncr.27514
49.Fojo T, Grady C.How much is life worth: cetuximab, non-small cell lung cancer and the $440 billion question. J Natl Cancer Inst. 2009;101:1044–1048.